With 100 million new internet users every year, Amazon is betting big on India, but a major new investment in homegrown rival Flipkart means the battle to dominate the fast-growing e-commerce market is set to heat up.
Flipkart announced this week that top international companies including Microsoft, eBay and China's Tencent had pledged investments totalling $1.4 billion, among the largest sums ever raised by an Indian start-up.
The 10-year-old e-commerce company needs all the help it can get to compete with Amazon after the Seattle-based giant made India's 1.25 billion inhabitants a global strategic priority, earmarking $5 billion in investment funds.
"They need to have a substantial amount of cash in order to fight in the market with Amazon," said Jaideep Mehta, South Asia director at the International Data Corporation.
Every three seconds, an Indian connects to the internet for the first time, according to Google.
One in three Indians currently uses the internet, but the number is forecast to swell by 300 million by 2020, mainly due to growing smartphone use.
McKinsey analyst Ashish Tuteja said 70 percent of online sales in India were done on a smartphone.
"It's very much a mobile-first market," he said.
Projections for the size of the market by 2020 differ wildly, ranging from $50 billion to $120 billion.
But all agree that it will be worth considerably more than the current $15 billion, thanks to an expanding middle class and rapidly growing internet use.
Amazon only opened its doors in India in 2013, but quickly overtook local start-up Snapdeal to become the second-biggest player.
E-retailers in India typically adopt a "marketplace" structure, acting as platforms that connect buyers and sellers rather than stocking their own products.
Amazon marketed its services aggressively, touring markets around the country with its "chai carts" to sell the idea of e-commerce to small traders over a cup of tea.
Under another initiative dubbed "Feet-on-Street", an Amazon employee would be sent to photograph their products and help them to sign up online.
Flipkart, Amazon and Snapdeal are now engaged in a price war, with each Indian festival an occasion for aggressive cuts.
"At some point, they will have to make money," said Mehta - something experts say will necessitate consolidation of the sector.
That process has already begun, with Flipkart absorbing two rival portals, Myntra and Jabong. According to Indian media, a deal for Flipkart to buy Snapdeal is next.
India also represents a chance for a rematch after Amazon lost out to Alibaba in China. Although currently more focused on Southeast Asia, billionaire Jack Ma's group has made no secret of its interest in India.
The Chinese giant has taken a stake in Indian online payments company Paytm and has ambitions to develop as an online sales platform in its own right.
For Amazon, India is the "last big frontier", said Mehta.
"Amazon is a 100-billion-dollars-plus retailer. To keep driving growth, they need to keep leadership positions in large markets outside the US," he said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.